cardiogenic shock

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

By MedXY 12/12/2025

A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarkers of gut, renal, hepatic injury or inflammation.

Cardiology Critical Care news

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock

By MedXY 12/09/2025

A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.

Cardiology Critical Care news

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

By MedXY 12/09/2025

In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Cardiology Critical Care news Specialties

C-Reactive Protein as a Prognostic Biomarker in Infarct-Related Cardiogenic Shock: Insights from the ECLS-SHOCK Trial

By MedXY 08/16/2025

Elevated CRP levels independently predict short-term mortality in acute myocardial infarction complicated by cardiogenic shock, with extracorporeal life support showing no survival benefit regardless of CRP levels or admission timing.